Long-term effectiveness of benralizumab in severe eosinophilic asthma patients treated for 96-weeks: data from the ANANKE study.

MLA

Vultaggio, Alessandra, et al. “Long-Term Effectiveness of Benralizumab in Severe Eosinophilic Asthma Patients Treated for 96-Weeks: Data from the ANANKE Study.” Respiratory Research, vol. 24, no. 1, May 2023, p. 135. EBSCOhost, https://doi.org/10.1186/s12931-023-02439-w.

APA

Vultaggio, A., Aliani, M., Altieri, E., Bracciale, P., Brussino, L., Caiaffa, M. F., Cameli, P., Canonica, G. W., Caruso, C., Centanni, S., D’Amato, M., De Michele, F., Del Giacco, S., Di Marco, F., Menzella, F., Pelaia, G., Rogliani, P., Romagnoli, M., Schino, P., … Schroeder, J. W. (2023). Long-term effectiveness of benralizumab in severe eosinophilic asthma patients treated for 96-weeks: data from the ANANKE study. Respiratory Research, 24(1), 135. https://doi.org/10.1186/s12931-023-02439-w

Chicago

Vultaggio, Alessandra, Maria Aliani, Elena Altieri, Pietro Bracciale, Luisa Brussino, Maria Filomena Caiaffa, Paolo Cameli, et al. 2023. “Long-Term Effectiveness of Benralizumab in Severe Eosinophilic Asthma Patients Treated for 96-Weeks: Data from the ANANKE Study.” Respiratory Research 24 (1): 135. doi:10.1186/s12931-023-02439-w.